Therapeutic Antibodies

Female researcher in a laboratory
#Biologics #Biomanufacturing #Monoclonal antibodies #Phylloceuticals #Plant-based

US company hopes to transform access to advanced biologics

Phylloceuticals has announced the successful production of its first batch of a PD-1 inhibitor monoclonal antibody (mAb) just 12 weeks after initiating operations in its new laboratory space in Rapid City, South Dakota, US.   The company says the achievement marks a potential paradigm shift in how complex… Read More

#News

Monoclonal antibody
#AbbVie #Autoimmune disease #Bi- and trispecifics #Mergers and acquisitions #Monoclonal antibodies #Oncology

AbbVie licenses trispecific antibody in billion-dollar contract

IGI Therapeutics, a wholly owned subsidiary of Ichnos Glenmark Innovation, and AbbVie have announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, for oncology and autoimmune diseases.  “Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more… Read More

#Business & Investment #News

Bladder
#AstraZeneca #Bladder cancer #European Commission #Monoclonal antibodies #Oncology

EU-approved bladder cancer therapy reduces death risk by 25%

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment.  According to the decision, this treatment should be followed by Imfinzi as monotherapy adjuvant treatment… Read More

#Cancer Research #News #Regulatory

Antibody
#Antibodies #argenx #Biology #Biotechnology #Drug development #Drug discovery #Muscles

argenx advances ARGX-119 in congenital myasthenic syndromes 

argenx has announced it will advance ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS). The decision follows the analysis of topline data from the Phase Ib study, in which ARGX-119 demonstrated a favourable safety and tolerability profile. “The… Read More

#News

#Antibody engineering #Antibody-based therapeutics #eBook #Monoclonal antibodies #Therapeutic Antibodies

eBook: The significance of mAbs in drug discovery and development

Monoclonal antibodies (mAbs), thanks to their low toxicity and high specificity, have enjoyed incredible market success across a range of disease categories. Of the 2024 top 10 bestselling drugs, half were mAbs, with Merck’s Keytruda (pembrolizumab) in the lead, followed by Abbvie’s Humira (adalimumab), Sanofi and… Read More

#News

Research scientists in laboratory
#Arialys Therapeutics #Autoimmune disease #Neuropsychiatric disorders #Neuroscience #Preclinical investigations #Therapeutic Antibodies

Study supports monovalent antibody in neuropsychiatric disease

New preclinical data have demonstrated that Arialys Therapeutics’ lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioural symptoms in a non-human primate model.   The company says the findings support the continued clinical development… Read More

#Editor's Choice #News

Human eye
#AMD #Monoclonal antibodies #Ophthalmology #Outlook Therapeutics #Scottish Medicines Consortium (SMC)

Bevacizumab gamma gets Scottish OK for wet AMD

The Scottish Medicines Consortium (SMC) has approved Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD).   It is the first licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU and the UK and has an initial… Read More

#News #Regulatory

Baby on a respirator - RSV
#FDA #Merck #Monoclonal antibodies #Paediatrics #Respiratory syncytial virus

FDA approves Merck’s Enflonsia for RSV prevention

The US Food and Drug Administration (FDA) has approved Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV season.   Enflonsia is a preventive, long-acting monoclonal antibody (mAb) designed… Read More

#News #Regulatory

#Therapeutic Antibodies

Case Study – Synthesis & Characterization of Trastuzumab-Based ADCs Using Fluorescent & Cytotoxic Payloads

Delve into our case studies on ADC Synthesis, Development, and Characterization, where we reveal how: Trastuzumab-based ADCs with multiple payload linkers demonstrated specific, targeted functional activity. Flow cytometry and internalization assays confirmed antigen targeting and cellular uptake. Cytotoxicity assays revealed nanomolar IC50s only in HER2+ cell lines, confirming ADC efficacy… Read More

#Case Studies

Antibodies
#Absci #Antibodies #Biologics #Biopharmaceuticals #Clinical trials

Absci becomes clinical-stage company with clinical trial initiation

Biopharmaceutical company Absci has transitioned into a clinical-stage organisation with the dosing of patients in its Phase I clinical trial of ABS-101. ABS-101 is the company’s investigational anti-TL1A antibody targeting inflammatory bowel disease, engineered using Absci’s generative AI platform. “We are excited to advance ABS-101 into Phase I clinical trials,”… Read More

#News

Lung cancer
#European Commission #Lung cancer #Monoclonal antibodies #Oncology

European Commission approves Tevimbra for small cell lung cancer

The European Commission has approved Tevimbra (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC).  The new indication is based on results of RATIONALE-312 study, which demonstrated statistically significant overall survival benefit for patients… Read More

#News #Regulatory

Monoclonal antibody
#Crohn's disease #European Commission #Inflammatory Bowel Disease #Johnson & Johnson #Monoclonal antibodies

New EU approval for Johnson & Johnson’s guselkumab

The European Commission (EC) has approved Tremfya (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for adult patients with moderately to severely active Crohn’s disease.  The approval is based on data which showed that guselkumab induction therapy administered either intravenously… Read More

#News #Regulatory

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Bispecific Antibodies #Cancer research #Solid tumours #SOTIO

The challenges in solid tumour targeting with bispecific ADCs

Czech biotechnology company, SOTIO, recently started preclinical development of its first two bispecific antibody drug conjugates (ADCs), which it says are “just the beginning” of what it has in store for its next-generation ADC pipeline. DDW’s Megan Thomas speaks with SOTIO’s Chief Scientific Officer, Martin Steegmaier, about the company’s pipeline. Read More

#Cancer Research #Exclusive Content

#Antibodies #Cell analysis #Cell therapy #Drug discovery #Single-cell analysis

How real-time analysis of single cells can advance drug discovery  

DDW Editor Reece Armstrong speaks to Vikram Devgan, PhD, VP of Global Marketing and Product Management, Bruker Cellular Analysis, about how real-time access to single cells can drive functional insights.   RA: How has single-cell research evolved over the past two decades?  VD: Single-cell… Read More

#Exclusive Content

ulcerative colitis
#European Commission #Johnson & Johnson #Monoclonal antibodies #Ulcerative colitis (UC)

Guselkumab approved in the EU for ulcerative colitis

The European Commission (EC) has approved a marketing authorisation (MA) for Johnson & Johnson’s Tremfya (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).  It is approved in patients who had an inadequate response, lost response, or were intolerant to either… Read More

#News #Regulatory

Monoclonal antibodies
#Monoclonal antibodies #Multiple sclerosis #Phase II trial #Tiziana Life Sciences #University of Massachusetts

UMass joins Phase II trial for multiple sclerosis

The University of Massachusetts (UMass) has begun dosing participants with Tiziana Life Sciences’ lead development candidate, intranasal foralumab, as part of an ongoing Phase II trial in patients with non-active secondary progressive multiple sclerosis (na-SPMS). UMass joins Brigham and Women’s Hospital (BWH), Yale Multiple Sclerosis Center, and Johns… Read More

#News